Evolus, Inc. (EOLS)

Evolus, Inc (EOLS) is a medical aesthetics company that focuses on providing physicians and patients with advanced aesthetic treatments and procedures. The company's flagship product is Jeuveau, a botulinum toxin type A injection that is used to improve the appearance of glabellar lines or frown lines between the eyebrows. Jeuveau is the first and only neurotoxin to be developed solely for aesthetics and was approved by the FDA in 2019.

Evolus' mission is to offer consumers a premium experience at a more affordable price. The company's marketing strategy is to target millennial and generation X consumers, who are more likely to be interested in preventative cosmetic procedures, and to partner with physicians who are looking to expand their aesthetic offerings. Evolus believes that there is significant market opportunity in the aesthetics industry, particularly in the United States, where there is a growing demand for non-invasive cosmetic treatments.

In addition to Jeuveau, Evolus has a number of other products in development, including DWP-450, a topical treatment for wrinkles and other signs of aging. The company also has a number of patent applications pending, covering various aspects of Jeuveau and other products.

The company is headquartered in Newport Beach, California and has a global presence, with operations in the United States, Canada, and Europe.